Hitech Windlass, Managing Director of Windlass Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.IPO-bound Windlass Biotech plans to build CDMO injectable biz, trade generics
Hitech Windlass, Managing Director of Windlass Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.
Subscribe to:
Post Comments (Atom)
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
No comments:
Post a Comment